INT87322

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.47
First Reported 1999
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 23
Total Number 23
Disease Relevance 15.73
Pain Relevance 4.68

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (ITGAL) cell adhesion (ITGAL) plasma membrane (ITGAL)
Anatomy Link Frequency
T cells 8
leukocyte 3
Lymphocytes 2
endothelial cells 1
plaques 1
ITGAL (Homo sapiens)
Pain Link Frequency Relevance Heat
postherpetic neuralgia 11 98.84 Very High Very High Very High
Inflammation 177 98.20 Very High Very High Very High
psoriasis 425 96.92 Very High Very High Very High
cytokine 173 92.36 High High
methotrexate 30 91.08 High High
Inflammatory response 4 90.88 High High
aspirin 3 89.92 High High
cINOD 14 89.56 High High
chemokine 24 88.92 High High
metalloproteinase 15 81.44 Quite High
Disease Link Frequency Relevance Heat
Adhesions 114 99.76 Very High Very High Very High
Endometriosis 126 99.64 Very High Very High Very High
Nicotine Addiction 66 99.44 Very High Very High Very High
Infection 120 99.36 Very High Very High Very High
Acquired Immune Deficiency Syndrome Or Hiv Infection 278 99.12 Very High Very High Very High
Post Operative Pain 11 98.84 Very High Very High Very High
Leukocytosis 10 98.58 Very High Very High Very High
INFLAMMATION 188 98.20 Very High Very High Very High
Psoriasis 493 97.24 Very High Very High Very High
Progressive Multifocal Leukoencephalopathy 1 96.96 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Lymphocytes from healthy subjects were preincubated with various concentrations of these substances and adhesion to plastic bound CD11a/CD18, CD11c/CD18, CD44 and CD62L mAbs was determined.
CD11a Binding (bound) of in Lymphocytes associated with adhesions
1) Confidence 0.47 Published 1999 Journal Pol. Arch. Med. Wewn. Section Abstract Doc Link 10740409 Disease Relevance 0.76 Pain Relevance 0.38
Efalizumab inhibits T-cell activation, cutaneous trafficking, and adhesion to keratinocytes through the blockade of LFA-1/ICAM-1 binding, steps in the immunologic cascade that lead to the formation of the psoriatic plaques (Menter et al 2005).
LFA-1 Binding (binding) of in plaques associated with psoriasis and adhesions
2) Confidence 0.38 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727906 Disease Relevance 0.73 Pain Relevance 0.07
Efalizumab is a humanized, monoclonal antibody, which targets CD11a, one of the subunits of leukocyte function-associated antigen-1.
CD11a Binding (targets) of in leukocyte
3) Confidence 0.36 Published 2004 Journal Dermatol Ther Section Abstract Doc Link 15379774 Disease Relevance 0.29 Pain Relevance 0.17
Efalizumab is a humanized monoclonal antibody that binds to CD11a, the alpha-subunit of lymphocyte function-associated antigen-1, and consequently inhibits T-cell activation.
CD11a Binding (binds) of in T-cell
4) Confidence 0.35 Published 2005 Journal Am J Clin Dermatol Section Abstract Doc Link 15799683 Disease Relevance 0.22 Pain Relevance 0.07
This drug binds to CD11a on T cells blocking the interaction between LFA-1 and intercellular adhesion molecule 1 (ICAM-1), its partner molecule for adhesion.
CD11a Binding (binds) of in T cells associated with adhesions
5) Confidence 0.26 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721342 Disease Relevance 0.30 Pain Relevance 0.03
This drug binds to CD11a on T cells blocking the interaction between LFA-1 and intercellular adhesion molecule 1 (ICAM-1), its partner molecule for adhesion.
LFA-1 Binding (interaction) of in T cells associated with adhesions
6) Confidence 0.20 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721342 Disease Relevance 0.31 Pain Relevance 0.03
Efalizumab, an LFA-1 inhibitor (Lymphocyte function associated Antigen-1), was withdrawn from the market in 2010 because of concerns with progressive multifocal leukoencephalopathy, and its cutaneous SLE trial was suspended.
LFA-1 Binding (associated) of in Lymphocyte associated with progressive multifocal leukoencephalopathy and systemic lupus erythematosus
7) Confidence 0.13 Published 2010 Journal BMC Med Section Body Doc Link PMC3009611 Disease Relevance 0.79 Pain Relevance 0.17
The third mechanism is unrelated to inhibition of HMG-CoA reductase, and consist in blocking the interaction between LFA-1 and ICAM-1 adhesion molecules [30], which is crucial to stabilize antigen presenting cell/T-cell contact during antigen presentation and to regulate the traffic of leukocytes during homeostatic and inflammatory conditions [31,32].
LFA-1 Binding (interaction) of in T-cell associated with inflammation and adhesions
8) Confidence 0.10 Published 2009 Journal Trials Section Body Doc Link PMC2705367 Disease Relevance 0.44 Pain Relevance 0.11
Therefore, the pathogenesis of HIV-1 infection can be modulated by the ICAM-1/LFA-1 interaction through modulatory effects on cell to-cell transmission of HIV-1, virus replication, virus-mediated syncytium formation, depletion of CD4 T cells, and destruction of the architecture of secondary lymphoid organs [57-62].
LFA-1 Binding (interaction) of in T cells associated with acquired immune deficiency syndrome or hiv infection and infection
9) Confidence 0.10 Published 2009 Journal Trials Section Body Doc Link PMC2705367 Disease Relevance 0.87 Pain Relevance 0
In this regard, particular attention has been directed at the physiological and pathological roles played by intercellular adhesion molecule (ICAM-1), a 76-114-kDa surface glycoprotein that has five extracellular immunoglobulin-like domains [11-14].Transmigration of leukocytes involves high-affinity binding of LFA-1 or Mac-1 on their surface to ICAM-1 expressed on the endothelium [10].
LFA-1 Binding (binding) of in leukocytes associated with adhesions
10) Confidence 0.09 Published 2006 Journal Reprod Biol Endocrinol Section Body Doc Link PMC1403781 Disease Relevance 0.49 Pain Relevance 0.21
CD11a (LFA-1) and its ligand play an important role in the interaction between antigen presenting cells and T-lymphocytes.
LFA-1 Binding (ligand) of in T-lymphocytes
11) Confidence 0.08 Published 2005 Journal Respir Res Section Body Doc Link PMC1187924 Disease Relevance 1.48 Pain Relevance 0.28
Statins could possibly act on distinct levels for controlling HIV-1 replication: a) by lowering cholesterol, they could slow down the cell cycle, modify several signalling pathways and diminish viral entry and budding; b) by inhibiting the prenylation of small GTPases, they could hinder cell movement and decrease expression or affinity level of immune molecules such as LFA-1 and ICAM-1, c) by modulating CCR5 and RANTES expression, they could hamper the infection of target cells by R5 tropic viruses, and d) by blocking LFA-1/ICAMs interaction, they could attenuate several components of inflammatory, immunologic and virological responses.
LFA-1 Binding (interaction) of associated with inflammation, acquired immune deficiency syndrome or hiv infection and infection
12) Confidence 0.08 Published 2009 Journal Trials Section Body Doc Link PMC2705367 Disease Relevance 1.33 Pain Relevance 0.11
Efalizumab is a humanized monoclonal IgG antibody that binds to the alpha-subunit (CD11) of LFA-1 and prevents LFA-1 binding to ICAM-1.
CD11 Binding (binds) of
13) Confidence 0.07 Published 2005 Journal J Immune Based Ther Vaccines Section Body Doc Link PMC1208938 Disease Relevance 1.26 Pain Relevance 0.39
Efalizumab is a humanized monoclonal IgG antibody that binds to the alpha-subunit (CD11) of LFA-1 and prevents LFA-1 binding to ICAM-1.
LFA-1 Binding (binding) of
14) Confidence 0.07 Published 2005 Journal J Immune Based Ther Vaccines Section Body Doc Link PMC1208938 Disease Relevance 1.25 Pain Relevance 0.38
These bind corresponding ligands VLA-4 and LFA-1 respectively on eosinophils that leads to adhesion and transendothelial migration.
LFA-1 Binding (bind) of in eosinophils associated with adhesions
15) Confidence 0.04 Published 2004 Journal Clin Mol Allergy Section Body Doc Link PMC425596 Disease Relevance 0.72 Pain Relevance 0.24
MAb LFA-1 (recognizes CD11a) was a gift from Prof.
LFA-1 Binding (recognizes) of
16) Confidence 0.04 Published 2006 Journal J Inflamm (Lond) Section Body Doc Link PMC1435878 Disease Relevance 0.37 Pain Relevance 0.06
With its dual mechanism of action, alefacept blocks the interaction between the leukocyte-function-associated antigen (LFA)-3 and CD2 and thereby impedes the activation and proliferation of T cells.
LFA Binding (interaction) of in leukocyte
17) Confidence 0.03 Published 2007 Journal Therapeutics and Clinical Risk Management Section Abstract Doc Link PMC2386357 Disease Relevance 0.28 Pain Relevance 0.09
Soluble forms of ICAM-1 (s-ICAM-1) secreted by PF endometrial cells/endometriotic lesions can also bind to LFA-1 presenting lymphocytes and could prevent the recognition of endometrial cells by these lymphocytes and prevent subsequent NK cell-mediated cytotoxicity [57,58].
LFA-1 Binding (bind) of in NK cell associated with endometriosis
18) Confidence 0.03 Published 2003 Journal Reprod Biol Endocrinol Section Body Doc Link PMC305339 Disease Relevance 0.98 Pain Relevance 0.21
Thus, blocking LFA-1 interactions has the dual effect of blocking activation as well as migratory activity of inflammatory T cells.
LFA-1 Binding (interactions) of in T cells associated with inflammation
19) Confidence 0.03 Published 2008 Journal Indian Journal of Pharmacology Section Body Doc Link PMC2792605 Disease Relevance 0.46 Pain Relevance 0.14
In a longterm clinical study, 50% of 228 patients with chronic plaque psoriasis achieved PASI 75 after 15 months of continuous efalizumab treatment, suggesting sustained efficacy with efalizumab.[24] Efalizumab was approved for treatment of psoriasis by FDA in 2003.[25] Administration of efalizumab induces a peripheral leukocytosis (predominantly of CD8+ memory cells), which is due to blockade of the LFA-1/ICAM-1 interaction between T cells and endothelial cells.
LFA-1 Binding (interaction) of in endothelial cells associated with psoriasis and leukocytosis
20) Confidence 0.03 Published 2008 Journal Indian Journal of Pharmacology Section Body Doc Link PMC2792605 Disease Relevance 0.47 Pain Relevance 0.27

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox